Venur Vyshak Alva, Joshi Monika, Nepple Kenneth G, Zakharia Yousef
Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA.
Drug Des Devel Ther. 2017 Apr 11;11:1175-1182. doi: 10.2147/DDDT.S110209. eCollection 2017.
Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.
几种靶向血管内皮生长因子受体的酪氨酸激酶抑制剂以及抑制雷帕霉素哺乳动物靶点的分子正被用于治疗转移性肾细胞癌（mRCC）；然而，仍有改进的潜力。像纳武单抗这样的免疫检查点抑制剂和其他PD-1/PD-L1抑制剂为mRCC患者提供了另一种治疗方法。在本文中，作者回顾了纳武单抗治疗mRCC的1期、2期和3期临床试验的安全性和结果。
